Elsa D.
- Country
- Spain
- Department
- Oncology
Research Overview
- Evaluation of Neoadjuvant Patritumab Deruxtecan With or Without Endocrine Therapy in Treatment-Naïve HR+/HER2- High-Risk Early Breast Cancer Patients
- Phase III Non-Inferiority Trial of Ribociclib and Endocrine Therapy Versus Chemotherapy Plus Ribociclib in HR+ HER2- Intermediate-Risk Early Breast Cancer
- CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Data & Insights
Has run more than one trial at 50 of 324 partner sites.
Specializations
Breast Cancer Therapeutics
This investigator specializes in advancing treatments for various subtypes of breast cancer, with particular emphasis on targeted therapeutic approaches for specific molecular profiles.
- HER2-positive breast cancer treatment optimization
- Post-neoadjuvant therapy management
- Residual disease treatment strategies
The research focus includes evaluating novel peptide-based immunotherapies and combination treatment approaches for high-risk patients.
Triple Negative Breast Cancer
Dedicated to investigating innovative treatment options for triple negative breast cancer, particularly in the post-surgical setting following neoadjuvant therapy.
- Antibody-drug conjugate applications
- Immunotherapy combinations
- Post-surgical treatment optimization
The investigator explores comparative effectiveness of various therapeutic approaches in managing residual invasive disease.
Hormone Receptor-Positive Disease
Focuses on advancing treatment options for estrogen receptor-positive, HER2-negative early breast cancer, with emphasis on endocrine therapy innovations.
- Novel endocrine therapy approaches
- Adjuvant treatment strategies
- Personalized medicine applications
The research encompasses comparative studies of emerging endocrine therapies against established treatment standards.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.